Brand | Abnova |
Product type | Primary antibodies |
Reactivity | Human |
Host species | Mouse |
Applications | Flow Cyt |
Brand: | Abnova |
Reference: | MAB4582 |
Product name: | IL2RA monoclonal antibody, clone MEM-181 (FITC) |
Product description: | Mouse monoclonal antibody raised against native IL2RA. |
Clone: | MEM-181 |
Isotype: | IgG1 |
Gene id: | 3559 |
Gene name: | IL2RA |
Gene alias: | CD25|IDDM10|IL2R|TCGFR |
Gene description: | interleukin 2 receptor, alpha |
Immunogen: | Native purified IL2RA from PHA-activated peripheral blood leucocytes. |
Form: | Liquid |
Recommend dilutions: | Flow Cytometry (20 ul in human blood cells 100 ul in whole blood or 106 cells in a suspension) The optimal working dilution should be determined by the end user. |
Storage buffer: | In PBS (0.2% BSA, 0.09% sodium azide) |
Storage instruction: | Store in the dark at 4°C. Do not freeze. Avoid prolonged exposure to light. Aliquot to avoid repeated freezing and thawing. |
Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
Conjugate tag: | FITC |
Product type: | Primary antibodies |
Host species: | Mouse |
Specificity: | This antibody reacts with CD25 (Interleukin-2 receptor alpha chain), a 55 KDa type I transmembrane glycoprotein expressed on activated B and T lymphocytes, activated monocytes/macrophages and on CD4+ T lymphocytes (T regulatory cells); it is lost on resting B and T lymphocytes. |
Reactivity: | Human |
Application image: | ![]() |
Application image note: | Surface staining of human PBMC with IL2RA monoclonal antibody, clone MEM-181 (FITC) (Cat # MAB4582). The mononuclear cells were isolated from human peripheral blood, devided in aliquots for duplicate analysis and stimulated with PHA for 2 days. Panel A, C : staining with the IL2RA monoclonal antibody, clone MEM-181 (Cat # MAB0882). Panel B, D : staining with the standard IL2RA monoclonal antibody. |
Applications: | Flow Cyt |
Shipping condition: | Blue Ice |
Publications: | Advances in interleukin 2 receptor targeted treatment.Morris JC, Waldmann TA. Ann Rheum Dis. 2000 Nov;59 Suppl 1:i109-14. |